Dextrose Monohydrate 70% Injection shortage
Dextrose Monohydrate 70% Injection is currently listed in shortage by the FDA. The FDA lists 4 affected products. The reported reason: Other. This page was last refreshed from FDA data on Oct 2, 2026.
Dextrose Monohydrate 70% Injection has been on the FDA shortage list for over a year. All three manufacturers reporting the shortage still list supply available at the 70 g/100 mL strength, though Baxter Healthcare does not expect full recovery until September 2026.
Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers and your prescriber about a long-term plan.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Dextrose Monohydrate 70% Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 22, 2026Currently in shortage4 of 4 products affected.
-
Sep 17, 2026FDA refreshed this shortage record1 product updated.
-
Sep 16, 2026FDA refreshed this shortage record2 products updated.
-
Oct 11, 2024First reported to the FDA4 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: B. Braun Medical Inc. 📞 800-227-2862 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50) | — | Available | — | — |
Manufacturer: Baxter Healthcare 📞 888-229-0001 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06) | — | Limited Availability | Estimated recovery: September 2026 | Other |
Manufacturer: Otsuka ICU Medical LLC 📞 1-866-829-9025 or [email protected] 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19) | — | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — |
| Current | DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07) | — | Available | This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical. | — |
These rows are manufacturer reports to the FDA for Dextrose Monohydrate 70% Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Dextrose Monohydrate 70% Injection? options further down this page.
Why is Dextrose Monohydrate 70% Injection in shortage?
Right now, Baxter Healthcare is reporting limited supply of their Dextrose Monohydrate 70% Injection (70 g/100 mL). The FDA has listed the reason simply as "other," which means Baxter hasn't shared a specific public explanation for what's causing the supply issue. What we do know is that Baxter estimates their supply should recover by September 2026.
It's worth knowing that this shortage report only reflects what Baxter filed with the FDA. Other manufacturers — B. Braun Medical and Otsuka/ICU Medical — are also reporting their 70 g/100 mL versions of this same product as currently available, according to this same FDA report.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Dextrose Monohydrate 70% Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Dextrose Monohydrate 70% Injection?
Dextrose Monohydrate 70% Injection is currently listed on the FDA drug-shortage list. The only strength this product comes in — 70 g/100 mL — still has an available source, so there is a good chance your pharmacy can get the exact product you use.
This shortage has lasted more than a year, and the FDA reason on file is listed simply as "Other." Even so, all three manufacturers on this record report supply of the 70 g/100 mL strength. Two of them (B. Braun and the version distributed by ICU Medical) report it as available, and one (Baxter) reports limited availability with an estimated recovery of September 2026. No strength is currently without a source.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order the 70 g/100 mL strength; they can check wholesalers and other manufacturers, since supply is still being reported.
- If your usual product is hard to find locally, ask your pharmacist or prescriber about equivalent options.
Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls. This is general, national information and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 4 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Dextrose 70 g/100mL | B. | 2000 ml | — | AP | FDA listed |
| Dextrose 70 g/100mL | Baxter | 2000 ml | — | AP | FDA listed |
| Dextrose 70 g/100mL | ICU | 6 pouches | — | AP | FDA listed |
| Dextrose 70 g/100mL | ICU | 12 pouches | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Dextrose Monohydrate 70% Injection — that fall in the same broad treatment class (iv solutions: dextrose-water) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other endocrinology/metabolism, gastroenterology, other, pediatric shortages
Dextrose Monohydrate 70% Injection shortage FAQs
Is Dextrose Monohydrate 70% Injection in shortage?
Why is Dextrose Monohydrate 70% Injection in shortage?
Which products are affected?
When will Dextrose Monohydrate 70% Injection be available again?
What should I do if I take Dextrose Monohydrate 70% Injection?
Still have a question about the Dextrose Monohydrate 70% Injection shortage?
Ask a pharmacist about this shortage →View Dextrose Monohydrate 70% Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.